Pyxis Oncology, Inc. (PYXS) Wednesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PYX-201, the company's drug candidate for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
The FDA's Fast Track designation program is intended to facilitate and expedite the development and review of new drugs in the U.S. for the treatment of a serious or life-threatening condition.
PYX-201 is currently being evaluated in multiple Phase 1 studies in various types of solid tumors.
For comments and feedback: editorial@rttnews.com